Afficher la notice abrégée

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAVINA, Marion
dc.contributor.authorLITIERE, Saskia
dc.contributor.authorITALIANO, Antoine
dc.contributor.authorBURZYKOWSKI, Tomasz
dc.contributor.authorBONNETAIN, Franck
dc.contributor.authorGOURGOU, Sophie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRONDEAU, Virginie
dc.contributor.authorBLAY, Jean Yves
dc.contributor.authorCOUSIN, Sophie
dc.contributor.authorDUFFAUD, Florence
dc.contributor.authorGELDERBLOM, Hans
dc.contributor.authorGRONCHI, Alessandro
dc.contributor.authorJUDSON, Ian
dc.contributor.authorLE CESNE, Axel
dc.contributor.authorLORIGAN, Paul
dc.contributor.authorMAUREL, Joan
dc.contributor.authorVAN DER GRAAF, Winette
dc.contributor.authorVERWEIJ, Jaap
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2021-01-05T08:38:35Z
dc.date.available2021-01-05T08:38:35Z
dc.date.issued2018-10-02
dc.identifier.issn1949-2553 (Electronic) 1949-2553 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23641
dc.description.abstractEnBackground: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. We evaluated the surrogate properties of progression-free survival (PFS), time-to-progression (TTP) and time-to-treatment failure (TTF) in advanced soft tissue sarcomas (STS). Results: A total of 21 trials originally met the selection criteria and 14 RCTs (N = 2846) were included in the analysis. Individual-level associations were moderate (highest for 12-month PFS: Spearman's rho = 0.66; 95% CI [0.63; 0.68]). Trial-level associations were ranked as low for the three endpoints as per the IQWiG criterion. Materials and Methods: We performed a meta-analysis using individual-patient data (IPD). Phase II/III RCTs evaluating therapies for adults with advanced STS were eligible. We estimated the individual- and the trial-level associations between then candidate surrogates and OS. Statistical methods included weighted linear regression and the two-stage model introduced by Buyse and Burzykowski. The strength of the trial-level association was ranked according to the German Institute for Quality and Efficiency in Health Care (IQWiG) guidelines. Conclusions: Our results do not support strong surrogate properties of PFS, TTP and TTF for OS in advanced STS.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enBiostatistics
dc.subject.enCIC1401
dc.subject.enEPICENE
dc.title.enSurrogate endpoints in advanced sarcoma trials: a meta-analysis
dc.title.alternativeOncotargeten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.18632/oncotarget.26166en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30349653en_US
bordeaux.journalOncotargeten_US
bordeaux.page34617-34627en_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue77en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.teamBIOSTAT_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03165439
hal.version1
hal.date.transferred2021-03-10T15:27:21Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Oncotarget&rft.date=2018-10-02&rft.volume=9&rft.issue=77&rft.spage=34617-34627&rft.epage=34617-34627&rft.eissn=1949-2553%20(Electronic)%201949-2553%20(Linking)&rft.issn=1949-2553%20(Electronic)%201949-2553%20(Linking)&rft.au=SAVINA,%20Marion&LITIERE,%20Saskia&ITALIANO,%20Antoine&BURZYKOWSKI,%20Tomasz&BONNETAIN,%20Franck&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_Oncotarget_2018_Savina.pdf
Taille:
1.568Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée